Patents Examined by Abigail M. Cotton
  • Patent number: 7220737
    Abstract: The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such as naloxone.
    Type: Grant
    Filed: September 3, 1998
    Date of Patent: May 22, 2007
    Assignee: Novoneuron, Inc
    Inventor: Deborah C. Mash
  • Patent number: 7199101
    Abstract: A gelling agent for an oil, which contains at least one compound (A) and at least one compound (B), and a gel composition containing the gelling agent and an oil: wherein R1 is a straight chain or branched chain, saturated or unsaturated hydrocarbon group having 7 to 17 carbon atoms, R2 is a straight chain or branched chain, saturated or unsaturated hydrocarbon group having 1 to 26 carbon atoms, R3 and R4 are each independently a straight chain or branched chain, saturated or unsaturated hydrocarbon group having 1 to 26 carbon atoms, and R5 is a straight chain or branched chain, saturated or unsaturated hydrocarbon group having 7 to 17 carbon atoms.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: April 3, 2007
    Assignee: Ajinomoto Co., Inc.
    Inventors: Toshihiko Hatajima, Naoya Yamato, Tatsuya Hattori
  • Patent number: 7179475
    Abstract: The present invention provides anhydrous compositions for topical delivery of a medicament comprising (A) a penetration enhancer/solvent selected from the group consisting of alcohol, propylene glycol, or a combination thereof; (B) a humectant/solvent selected from the group consisting of polyethylene glycol, glycerin, sorbitol, xylitol, or any combination of any of the foregoing; and (C) an anhydrous vehicle. In an alternate embodiment, the present invention provides anhydrous compositions for topical delivery of a medicament which comprise (A) a penetration enhancer/solvent selected from the group consisting of alcohol, propylene glycol, or a combination thereof; (B) a humectant/solvent selected from the group consisting of polyethylene glycol, glycerin, sorbitol, xylitol or any combination of any of the foregoing; (C) an anhydrous vehicle; and (D) a medicament.
    Type: Grant
    Filed: May 1, 2000
    Date of Patent: February 20, 2007
    Assignee: Johnson & Johnson Consumer Companies, Inc.
    Inventors: Katherine M. Burnett, Ellen S. Kurtz
  • Patent number: 7132458
    Abstract: This invention features fractionated oxidized carotenoid or retinoid mixtures, and individual components thereof, which are useful as cell-differentiation-inducing, anti-proliferative, anti-metastatic and anti-tumor agents. The mixtures and compounds of the invention can be used alone or in combination with other anticancer agents for the treatment of cancer.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: November 7, 2006
    Assignee: Chemaphor Inc.
    Inventors: Graham Burton, Janusz Daroszewski, Jenny Phipps, Prabhat Arya
  • Patent number: 7053077
    Abstract: The invention relates to the use of biogenic estrogen sulfamates for the oral discontinuous application for hormone replacement therapy (HRT). The discontinuous administration takes place in intervals ranging from 2 to 40 days. The invention also provides the additional application of gestagens, preferably continuously in the form of an implant or in the form of an intrauterine releasing system (IUD). Estrone sulfamate, estradiol sulfamate or an N-acyl sulfamate of estrone, estradiol or estriol having up to 7 C-atoms in the acyl chain, or a combination comprised of two or more of said active ingredients are used as biogenic estrogen sulfamates.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: May 30, 2006
    Assignee: Schering AG
    Inventors: Walter Elger, Pekka Lähteenmäki, Matti Lehtinen, Gudrun Reddersen, Holger Zimmermann, Michael Oettel, Sigfrid Schwarz
  • Patent number: 7045543
    Abstract: This invention herein describes a method of facilitating the entry of drugs into cells and tissues at physiologically protected sites at pharmacokinetically useful levels and also a method of targeting drugs to physiologically protected sites in vivo. Also provided are drug conjugates with an amino acid or derivative thereof for facilitating such targeted drug delivery. The conjugates and methods of this invention provide an advance over other drug targeting methods known in the prior art, because the invention provides drug concentrations in such physiologically protected sites that can reach therapeutically-effective levels after administration of systemic levels much lower than are currently administered to achieve a therapeutic dose. This technology is appropriate for use with psychotropic, neurotropic, neurological, antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drugs, agents and conjugates, for rapid and efficient introduction of such agents across, e.g.
    Type: Grant
    Filed: November 5, 2001
    Date of Patent: May 16, 2006
    Assignee: EnzRel Inc.
    Inventors: Milton B. Yatvin, Richard L. Pederson
  • Patent number: 7041683
    Abstract: Compounds of the formula useful for the treatment of depression and other conditions such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, sexual dysfunction, eating disorders, addictive disorders caused by ethanol or cocaine abuse and related illnesses.
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: May 9, 2006
    Assignee: Wyeth
    Inventors: George E. M. Husbands, Gary P. Stack, Richard E. Mewshaw, Ian A. Cliffe